Denali Therapeutics, Inc. (DNLI)
19.95
-0.46
(-2.25%)
USD |
NASDAQ |
May 07, 10:43
Denali Therapeutics Cash from Investing (Quarterly) : 20.77M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -209.50M |
| Neurocrine Biosciences, Inc. | -506.20M |
| Protalix Biotherapeutics, Inc. | -1.112M |
| Arcturus Therapeutics Holdings, Inc. | 0.0886M |
| Agenus, Inc. | 0.78M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -98.54M |
| Cash from Financing (Quarterly) | 192.13M |
| Free Cash Flow | -422.10M |
| Free Cash Flow Per Share (Quarterly) | -0.5703 |
| Free Cash Flow to Equity (Quarterly) | -97.95M |
| Free Cash Flow to Firm (Quarterly) | -100.06M |
| Free Cash Flow Yield | -12.26% |